GlassScriptPhysician profile
Phylicia Danielle Patterson
NPI 1578263026
$1,994.89
in general payments reported to CMS, 2019-2025
32 companies · $920 in 2025
The $920 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,049 · 2024: $25.24 · 2025: $920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673 · Education: $322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.56 |
| Education | $322.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $227.52 | 2023-2025 | Rybrevant, Erleada, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $175.16 | 2023-2025 | Enhertu, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $164.56 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Myriad Genetic Laboratories, INC. | $149.57 | 2023-2025 | Precisetumor |
| Pharmaessentia USA Corporation | $148.58 | 2023-2025 | Besremi |
| Astellas Pharma US INC | $126.86 | 2025 | Xtandi |
| Seagen INC. | $99.00 | 2025 | |
| Genzyme Corporation | $89.25 | 2023 | |
| Pfizer INC. | $73.06 | 2023-2025 | |
| Celgene Corporation | $65.31 | 2023-2024 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $60.70 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $52.17 | 2023-2025 | Opdivo |
| Glaxosmithkline, LLC. | $50.23 | 2023-2025 | Ojjaara, Blenrep |
| Cti Biopharma Corp. | $43.00 | 2023 | Vonjo |
| Abbvie INC. | $37.72 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $36.84 | 2023 | Jaypirca, Retevmo, Verzenio |
| Eisai INC. | $35.80 | 2023-2025 | |
| Array Biopharma INC | $31.08 | 2025 | Braftovi, Lorbrena |
| Apellis Pharmaceuticals, INC. | $30.29 | 2023 | Empaveli |
| Alexion Pharmaceuticals, INC. | $29.16 | 2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $28.74 | 2025 | Fruzaqla |
| Pharmacosmos Therapeutics INC. | $26.82 | 2025 | Monoferric |
| Genentech USA, INC. | $26.75 | 2023 | Tecentriq |
| Beone Medicines USA, INC. | $26.52 | 2025 | Brukinsa |
| Beigene USA, INC. | $23.59 | 2023 | Brukinsa |
| Nuvation Bio INC. | $22.03 | 2025 | Ibtrozi |
| Mirati Therapeutics, INC. | $21.66 | 2023 | Krazati |
| Daiichi Sankyo INC. | $21.20 | 2025 | Enhertu |
| Emd Serono, INC. | $20.41 | 2025 | |
| Springworks Therapeutics, INC. | $18.28 | 2025 | Ogsiveo |
| Amgen INC. | $17.35 | 2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $15.68 | 2023 | Libtayo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phylicia Patterson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.